Indian Urged To Boost IPP For Investment

15 October 1997

The Organization of Pharmaceutical producers of India, which representsthe Indian subsidiaries of foreign pharmaceutical companies and major local manufacturers, has urged the Indian government to institute strong intellectual property protection to encourage foreign investment in the pharmaceutical sector, and curtail the current brain drain from India.

OPPI has told the federal Ministry of Chemicals and Fertilizers that strong intellectual property rights will be instrumental in reversing this process, not only boosting the confidence of foreign investors but also putting a halt to the "world-renowned pool of scientific talent" moving out of the country.

Many multinational companies will be reluctant to introduce innovative new medicines in the absence of strong IPP, said OPPI's president, Mr D Bhadury. Only a strong patent law can encourage, stimulate and sustain innovation, he said, adding: "it appears that basically we have not developed the mindset to accept the fact of globalization and appreciate the reality that India cannot afford to stand isolated when its economy is globalizing."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight